Hasegawa Masatoshi, Uto Fumiaki, Asakawa Isao, Kajitani Chikae, Katayama Emiko, Okada Hiroshi, Hontsu Shigeto, Tamamoto Tetsuro
Dept. of Radiation Oncology, Nara Medical University, Nara, Japan.
Gan To Kagaku Ryoho. 2009 Dec;36(13):2537-41.
Positron emission tomography (PET), especially F-18 fluorodeoxyglucose (FDG)-PET, has been recently used to verify the target volume in radiation treatment planning (RTP) for malignancies. The utility of FDG-PET/CT in defining gross tumor volume (GTV) has been shown in many studies, and the target delineation by a fixed threshold of the maximum standardized uptake value (40-50%) is suggested to be useful in RTP for lung cancer, head and neck cancer, etc. But, the spatial resolution, sensitivity, and specificity of PET are not always enough to define the difference between the GTV and the clinical target volume(CTV). Furthermore, FDG-PET is frequently used in the clinical staging before the treatment, and is also applied to the response evaluation after the treatment. This review focuses on the developing applications of PET in radiation oncology.
正电子发射断层扫描（PET），尤其是F-18氟脱氧葡萄糖（FDG）-PET，最近已被用于在恶性肿瘤的放射治疗计划（RTP）中验证靶区体积。许多研究已表明FDG-PET/CT在定义大体肿瘤体积（GTV）方面的效用，并且建议通过最大标准化摄取值的固定阈值（40%-50%）进行靶区勾画，这在肺癌、头颈癌等的RTP中是有用的。但是，PET的空间分辨率、灵敏度和特异性并不总是足以界定GTV与临床靶区体积（CTV）之间的差异。此外，FDG-PET常用于治疗前的临床分期，也应用于治疗后的疗效评估。本综述重点关注PET在放射肿瘤学中的应用进展。
